Eczema (Atopic Dermatitis) Clinical Trials in San Francisco
View 51 new treatments for Eczema (Atopic Dermatitis) in San Francisco, CA, and nearby areas, such as Antioch, Berkeley, Concord, Daly City, Oakland, Richmond and Vallejo. Every day, Power helps hundreds of eczema patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Amlitelimab + Topical Corticosteroids for Atopic Dermatitis (AQUA)
Sanofi Clinic, Fremont + 1 more
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate response to prior biologic or oral JAKi therapy. The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and older on background TCS and have had an inadequate response to prior biologic or an oral JAKi therapy. Study details include: At the end of the treatment period, participants will have the option to enter the Long-Term Safety Study LTS17367 (RIVER-AD). The study duration will be up to 56 weeks for participants not entering the long-term safety study (LTS17367 [RIVER-AD]) including a 2 to 4-week screening, a 36-week randomized double-blind period, and a 16-week safety follow-up. The study duration will be up to 40 weeks for participants entering the long-term safety study (LTS17367 [RIVER-AD]) including a 2 to 4-week screening and a 36-week randomized double-blind period. The total treatment duration will be up to 36 weeks. The total number of visits will be up to 13 visits (or 12 visits for those entering the long-term safety study LTS17367 [RIVER-AD] study).Show More
Verified
Recruiting
Phase 3
Est. 3 - 6 Weeks
Unregistered Study Lead
Research Team
Dupilumab for Eczema
Research Clinic, San Francisco + 1 more
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
Recruiting
No Placebo Trial
Phase 4
Est. 3 - 12 Weeks
Jeffrey Cheng, MD, PhD
Principal Investigator
Dupilumab for Eczema
Regeneron Clinic, San Francisco + 3 more
This trial is testing a medication for treating eczema in people with skin of color. Eczema causes itchy, dry, and cracked skin. The medication aims to reduce these symptoms by calming the immune system. The study will also look at side effects, how much of the drug is in the blood at different times, and improvements in quality of life and mental health.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 3 - 12 Weeks
Clinical Trial Management
Study Director
Nemolizumab for Eczema
Galderma Clinic, Fremont + 2 more
Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
Waitlist
No Placebo Trial
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Lebrikizumab for Eczema
Eli Lilly Clinic, San Francisco + 2 more
This trial will test the safety and effectiveness of lebrikizumab in people with severe eczema who have already tried another treatment called Dupilumab. Lebrikizumab aims to reduce skin inflammation by blocking a protein that causes it.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 4 - 6 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Upadacitinib + Topical Corticosteroids for Eczema
AbbVie Clinic, Stanford + 1 more
The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
ABBVIE INC.
Study Director
Abrocitinib for Atopic Dermatitis/Eczema
Pfizer Clinic, San Francisco + 1 more
This trial is testing a pill called Abrocitinib to help people aged 12 and older with severe eczema. It aims to see if the pill can reduce inflammation and itching by blocking certain body chemicals. The study includes patients who have already participated in a related study.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
Pfizer CT.gov Call Center
Study Director
Lebrikizumab for Eczema
Eli Lilly Clinic, San Francisco + 4 more
This trial is testing the safety and effectiveness of lebrikizumab, a medication for eczema. It targets people with moderate-to-severe atopic dermatitis, including those from previous studies and new participants. Lebrikizumab works by blocking a protein that causes inflammation and itching.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
Linerixibat for Itching in Cholangitis
GlaxoSmithKline Clinic, San Francisco + 1 more
This trial is testing a medication called linerixibat to see if it can help reduce severe itching in people with a liver condition called Primary Biliary Cholangitis (PBC). The study will compare the effects of linerixibat to check its effectiveness and safety.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
GSK Clinical Trials
Study Director
Rocatinlimab for Atopic Dermatitis
Amgen Clinic, Fremont + 1 more
This trial is testing a medication called rocatinlimab to see if it works and is safe for teenagers. The medication can be used by itself or with other treatments. It aims to help by interacting with the immune system.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
MD
Study Director
Page 1 of 4
Frequently Asked Questions
Explore related conditions